Videos
A 59-Year-Old Man With Relapsed Follicular Lymphoma
Pamela L. Kunz, MD, discusses the most recent FDA approval of Lutathera (lutetium [Lu 177] dotatate) for the treatment of patients with gastroenteropancreatic NETs (GEP-NETs), including foregut, midgut, and hindgut tumors.
Madappa Kundranda, MD, PhD, discusses the frontline therapeutic options for patients with newly diagnosed hepatocellular carcinoma who are not candidates for surgery or transplant.
Arash Rezazadeh Kalebasty, MD, a hematologist/oncologist and research program director, Urologic Oncology, Norton Cancer Institute, discusses the safety profile of cabazitaxel in the CARD trial, which randomized patients with metastatic castration-resistant prostate cancer to cabazitaxel or one of 2 antiandrogen receptor agents, abiraterone acetate or enzalutamide.
Daniel P. Petrylak, MD, discusses the efficacy results from the CARD trial, which evaluated the radiographic progression-free survival of cabazitaxel combined with either abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer.<br />
Daniel J. George, MD, says that clinicians who treat prostate cancer have devoted the past 70 years to hormone therapy and androgen deprivation therapy, particularly for patients with metastatic disease. However, the emergence of agents like docetaxel, abiraterone acetate, and androgen receptor antagonists, like apalutamide and enzalutamide, have changed the landscape.<br />
Andrew Kuykendall, MD, discusses the background to the JAK2 inhibitor fedratinib (Inrebic), which was approved by the FDA in August 2019 for the treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis, including post–polycythemia vera or post–essential thrombocythemia MF.
James Mohler, MD, discusses the rationale for the latest updates to the National Comprehensive Cancer Network guidelines for genetic testing in prostate cancer.
William G. Wierda, MD, PhD, shares a message with community oncologists about the evolving treatment landscape for patients with chronic lymphocytic leukemia.
Matthew P. Goetz, MD, discusses how genomic assays can help identify patients with ER–positive breast cancer who will benefit from the addition of chemotherapy to endocrine therapy.
David H. Ilson, MD, PhD, discusses the current role of pembrolizumab in patients with gastric cancer or gastroesophageal junction adenocarcinoma based on the results from the KEYNOTE-062 trial.
Ghassan K. Abou-Alfa, MD, discusses the current role for ramucirumab for the treatment of patients with hepatocellular carcinoma in the second-line setting.
Enrique Grande, MD, discusses the characteristics of metastatic urothelial cancer, which rationalizes the use of atezolizumab in combination with platinum-based chemotherapy in the IMvigor130 trial, in patients with locally advanced or metastatic urothelial carcinoma.<br />
Pieter Sonneveld, MD, PhD, discusses how the findings from the phase III CASSIOPEIA trial inform current thinking about treating patients with multiple myeloma.
Robert L. Coleman, MD, professor of medicine, The University of Texas MD Anderson Cancer Center, explains the rationale for the VELIA trial of veliparib with frontline chemotherapy and maintenance in patients with high-grade ovarian cancer.
Refractory Hepatocellular Carcinoma
Marcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.
Cynthia X. Ma, MD, PhD discusses the challenges with understanding treatment duration for adjuvant endocrine therapy in patients with breast cancer.
Ryan Sullivan, MD, discusses the 5-year data pooled from the phase III COMBI-d and COMBI-v trials, which each studied dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with <em>BRAF V600</em>–mutant unresectable or metastatic melanoma.
Winston Tan, MD, discusses the work of the Florida Society for Clinical Oncology, which helps improve the treatment of patients with all cancers.
Paul A. Bunn, Jr., MD, discusses subsets of patients with lung cancer that can benefit more from enrolling on clinical trials with immunotherapy compared with patients who do not benefit as much from immunotherapeutic approaches. Immunotherapy does not work in every patient, Bunn notes.
George Sledge, Jr., MD, discusses the overall survival data of the phase III MONARCH-2 trial in advanced hormone receptor-positive, HER2-negative breast cancer.